Literature DB >> 2844221

Evaluation of the synthetic somatostatin analogue SMS 201-995 in patients with hypoglycaemia associated with hepatocellular carcinoma.

B I Joffe1, M C Kew, V R Panz, W J Kalk, R Shires, J Wing, H C Seftel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2844221      PMCID： PMC2246484          DOI： 10.1038/bjc.1988.170

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  9 in total

1.  Further observations on hypoglycaemia in hepatocellular carcinoma.

Authors:  A J McFadzean; R T Yeung
Journal:  Am J Med       Date:  1969-08       Impact factor: 4.965

2.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

3.  Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.

Authors:  P Gorden; C M Hendricks; C R Kahn; K Megyesi; J Roth
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

4.  Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue.

Authors:  R G Long; A J Barnes; T E Adrian; C N Mallinson; M R Brown; W Vale; J E Rivier; N D Christofides; S R Bloom
Journal:  Lancet       Date:  1979-10-13       Impact factor: 79.321

5.  Tumor hypoglycemia: deficient splanchnic glucose output and deficient glucagon secretion.

Authors:  C K Silbert; A A Rossini; S Ghazvinian; W C Widrich; L J Marks; C T Sawin
Journal:  Diabetes       Date:  1976-03       Impact factor: 9.461

6.  Serum somatomedin and insulin levels in tumor hypoglycemia.

Authors:  B Joffe; M Kew; G Beaton; B Kusman; H Seftel
Journal:  J Endocrinol Invest       Date:  1978-07       Impact factor: 4.256

7.  Measurement of insulin-like growth factor II by a specific radioreceptor assay in serum of normal individuals, patients with abnormal growth hormone secretion, and patients with tumor-associated hypoglycemia.

Authors:  W H Daughaday; B Trivedi; M Kapadia
Journal:  J Clin Endocrinol Metab       Date:  1981-08       Impact factor: 5.958

8.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 9.  The riddle of tumour hypoglycaemia revisited.

Authors:  C R Kahn
Journal:  Clin Endocrinol Metab       Date:  1980-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.